Project Grant R21EY035974
Award Date 6/1/24
Completion Date 5/31/26
Dollars Obligated $408K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23219, USA
Similar Awards
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $295,500.00 to The Schepens Eye Research Institute, Inc. to develop a neuropeptide-based countermeasure to mitigate ocular damage from exposure to mustard gas agents. The research aims to assess the therapeutic efficacy of topical alpha-melanocyte-stimulating hormone (α-MSH) treatment in preventing corneal damage, nerve loss, and inflammation in a mouse model of...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,467,198.00 to the University of Connecticut Health Center (UCHC) to investigate the cellular and molecular mechanisms of corneal and sensory nerve damage caused by exposure to chemical warfare agents. The key products and services to be delivered under this 3-year award, which runs from September 15, 2025 to August...
- This Cooperative Agreement award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop a novel fenofibrate-loaded microemulsion (FENO-ME) eyedrop as a non-steroid treatment for nitrogen mustard (NM)-induced corneal injury. The $22,677 award to Virginia Commonwealth University (VCU) spans from Sep 2025 to May 2030. The project seeks to: 1) Validate PPARα signaling as a drug target for NM-induced corneal injury and optimize the FENO-ME eyedrop formulation; 2)...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program provides $498,248 to the University of Connecticut Health Center (UCHC) to investigate the molecular mechanisms underlying corneal and retinal injury caused by exposure to chemical threat agents like nitrogen mustard. The key objectives are to: 1) Examine the role of the p53-PAD axis in driving corneal hypercitrullination, a pathological response, after nitrogen...
- This $332,179 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports the development of nanobarrier contact lenses that can provide sustained delivery of the drug cysteamine to treat the ocular complications of cystinosis. The lenses are designed to replace the current 8-times daily eye drop regimen, improving patient compliance and reducing side effects from the preservatives and acidic pH in the eye drops. The project aims to demonstrate the lenses can...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will provide $937,468 to Northwestern University to understand the pathological mechanisms of sulfur mustard gas keratopathy (MGK) in the cornea. The research aims to explore how corneal mustard exposure induces autophagy, a cellular process that can play detrimental roles, via liberating the protein Beclin1 from the Beclin1-Bcl2 complex. The project will conduct in vitro and in...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $330,169 to ESK Therapeutics, Inc. to commercialize a biologic eyedrop formulation called CornealClear for the treatment of persistent corneal epithelial defects (PCED). The project aims to demonstrate that the CornealClear eyedrops can accelerate corneal wound healing and reduce scarring in a rabbit model, as well as confirm the systemic safety of the prolactin-induced protein (PIP) formulation. If...
- The Department of the Army Medical Command awarded a $1,428,860 Project Grant to The Schepens Eye Research Institute, Inc. of Boston, MA under the Military Medical Research and Development program (CFDA 12.420) to investigate the safety and efficacy of supersaturated oxygen emulsion (SSOE) as a novel topical treatment for open globe injury. The three-year award beginning September 30, 2022 will support animal research using mice to test SSOE and controls supplied by sub-awardee Coruna Medical...
- This Project Grant award of $204,875.00 from the National Eye Institute (CFDA 93.867 - Vision Research) to Clemson University aims to evaluate the efficacy of thymosin beta-4 (TB4) as a novel treatment for Acanthamoeba keratitis (AK), a serious eye infection that can lead to vision loss. The project has two key objectives: In vitro testing to determine the inhibitory effects of TB4 on Acanthamoeba parasites and its impact on host cell apoptosis and cytokine release. Ex vivo testing using porcine...
- The Defense Health Agency awarded a $498,896 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to The Schepens Eye Research Institute, Inc. in Boston, MA. The grant supports a 2-year research project investigating the use of noninvasive transpalpebral electrical stimulation as a therapy for combat-related corneal trauma. As an experienced performer of prior federal grants from agencies like the NIH, DoD, and Army, the non-profit Schepens Eye Research...